Cellular immunity in children with successful immunoprophylactic treatment for mother-to-child transmission of hepatitis B virus

BMC Infectious Diseases

Volumn 10, Issue , 2010, Pages

  Komatsu, Haruki ^a,b   Inui, Ayano ^a   Sogo, Tsuyoshi ^a   Hiejima, Eitaro ^a   Tateno, Akihiko ^b   Klenerman, Paul ^c   Fujisawa, Tomoo ^a  

^a Eastern Yokohama Hospital   (Japan)

^b TOHO UNIVERSITY   (Japan)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; HLA A24 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; VIRUS DNA; HEPATITIS B ANTIBODY; HLA ANTIGEN CLASS 1;

ADOLESCENT; ADULT; ARTICLE; CELLULAR IMMUNITY; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DNA DETERMINATION; DRUG EFFICACY; DRUG SPECIFICITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; INFANT; INFECTION PREVENTION; MALE; PLACENTAL TRANSFER; PRESCHOOL CHILD; REAL TIME POLYMERASE CHAIN REACTION; SCHOOL CHILD; VIREMIA; VIRUS CARRIER; VIRUS LOAD; VIRUS TRANSMISSION; BLOOD; IMMUNOLOGY; MIDDLE AGED; NEWBORN; SECRETION; SERUM; VERTICAL TRANSMISSION; VIROLOGY;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; DNA, VIRAL; FEMALE; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B VACCINES; HEPATITIS B VIRUS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNITY, CELLULAR; INFANT; INFANT, NEWBORN; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; INTERFERON-GAMMA; MALE; MIDDLE AGED; SERUM; T-LYMPHOCYTES, CYTOTOXIC; VIREMIA; YOUNG ADULT;

EID: 77951542796     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-10-103     Document Type: Article

References (32)

1. Beasley RP, Hwang LY, Lin CC, Chien CS. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan. Lancet 1981, 2(8256):1129-33. 10.1016/S0140-6736(81)90585-7, 6118576.
2. McMahon BJ, Alberts SR, Wainwright RB, Bulkow L, Lanier AP. Hepatitis B-related sequelae. Prospective study in 1400 hepatitis B surface antigen-positive Alaska native carriers. Arch Intern Med 1990, 150(5):1051-4. 10.1001/archinte.150.5.1051, 2158773.
3. Beasley RP, Trepo C, Stevens CE, Szmuness W. The e antigen and vertical transmission of hepatitis B surface antigen. Am J Epidemiol 1977, 105(2):94-8.
4. Slowik MK, Jhaveri R. Hepatitis B and C viruses in infants and young children. Semin Pediatr Infect Dis 2005, 16(4):296-305. 10.1053/j.spid.2005.06.009, 16210109.
5. Lee C, Gong Y, Brok J, Boxall EH, Gluud C. Effect of hepatitis B immunisation in newborn infants of mothers positive for hepatitis B surface antigen: systematic review and meta-analysis. BMJ 2006, 332(7537):328-36. 10.1136/bmj.38719.435833.7C, 1363909, 16443611.
6. Wong VC, Ip HM, Reesink HW, Lelie PN, Reerink-Brongers EE, Yeung CY, et al. Prevention of the HBsAg carrier state in newborn infants of mothers who are chronic carriers of HBsAg and HBeAg by administration of hepatitis-B vaccine and hepatitis-B immunoglobulin. Double-blind randomised placebo-controlled study. Lancet 1984, 1(8383):921-6. 10.1016/S0140-6736(84)92388-2, 6143868.
7. Stevens CE, Taylor PE, Tong MJ, Toy PT, Vyas GN, Nair PV, et al. Yeast-recombinant hepatitis B vaccine. Efficacy with hepatitis B immune globulin in prevention of perinatal hepatitis B virus transmission. JAMA 1987, 257(19):2612-6. 10.1001/jama.257.19.2612, 2952812.
8. Andre FE, Zuckerman AJ. Review: protective efficacy of hepatitis B vaccines in neonates. J Med Virol 1994, 44(2):144-51. 10.1002/jmv.1890440206, 7852954.
9. Matsumoto T, Nakata K, Hamasaki K, Daikokoku M, Nakao K, Yamashita Y, et al. Efficacy of immunization of high-risk infants against hepatitis B virus evaluated by polymerase chain reaction. J Med Virol 1997, 53(3):255-60. 10.1002/(SICI)1096-9071(199711)53:3<255::AID-JMV13>3.0.CO;2-G, 9365892.
10. Kato H, Nakata K, Hamasaki K, Hida D, Ishikawa H, Aritomi T, et al. Long-term efficacy of immunization against hepatitis B virus in infants at high-risk analyzed by polymerase chain reaction. Vaccine 1999, 18(7-8):581-7. 10.1016/S0264-410X(99)00320-5, 10547415.
11. Chisari FV, Ferrari C. Hepatitis B virus immunopathogenesis. Annu Rev Immunol 1995, 13:29-60. 10.1146/annurev.iy.13.040195.000333, 7612225.
12. Ota MO, Vekemans J, Schlegel-Haueter SE, Fielding K, Whittle H, Lambert PH, et al. Hepatitis B immunisation induces higher antibody and memory Th2 responses in new-borns than in adults. Vaccine 2004, 22(3-4):511-9. 10.1016/j.vaccine.2003.07.020, 14670334.
13. Sobao Y, Sugi K, Tomiyama H, Saito S, Fujiyama S, Morimoto M, et al. Identification of hepatitis B virus-specific CTL epitopes presented by HLA-A* the most common HLA class I allele in East Asia. J Hepatol 2402, 34(6):922-9.
14. Komatsu H, Inui A, Sogo T, Fujisawa T, Nagasaka H, Nonoyama S, et al. Large scale analysis of pediatric antiviral CD8+ T cell populations reveals sustained, functional and mature responses. Immun Ageing 2006, 3:11. 10.1186/1742-4933-3-11, 1784110, 17156440.
15. Tanaka H, Akaza T, Juji T. Report of the Japanese Central Bone Marrow Data Center. Clin Transpl 1996, 139-44.
16. Tokunaga K, Ishikawa Y, Ogawa A, Wang H, Mitsunaga S, Moriyama S, et al. Sequence-based association analysis of HLA class I and II alleles in Japanese supports conservation of common haplotypes. Immunogenetics 1997, 46(3):199-205. 10.1007/s002510050262, 9211745.
17. Sobao Y, Tomiyama H, Sugi K, Tokunaga M, Ueno T, Saito S, et al. The role of hepatitis B virus-specific memory CD8 T cells in the control of viral replication. J Hepatol 2002, 36(1):105-15. 10.1016/S0168-8278(01)00264-1, 11804672.
18. Liu Y, Hussain M, Wong S, Fung SK, Yim HJ, Lok AS. A genotype-independent real-time PCR assay for quantification of hepatitis B virus DNA. J Clin Microbiol 2007, 45(2):553-8. 10.1128/JCM.00709-06, 1829020, 17182753.
19. Bai H, Zhang L, Ma L, Dou XG, Feng GH, Zhao GZ. Relationship of hepatitis B virus infection of placental barrier and hepatitis B virus intra-uterine transmission mechanism. World J Gastroenterol 2007, 13(26):3625-30.
20. Michalak TI, Pasquinelli C, Guilhot S, Chisari FV. Hepatitis B virus persistence after recovery from acute viral hepatiti s. J Clin Invest 1994, 93(1):230-9. 10.1172/JCI116950, 293757, 8282792.
21. Penna A, Artini M, Cavalli A, Levrero M, Bertoletti A, Pilli M, et al. Long-lasting memory T cell responses following self-limited acute hepatitis B. J Clin Invest 1996, 98(5):1185-94. 10.1172/JCI118902, 507541, 8787682.
22. Yotsuyanagi H, Yasuda K, Iino S, Moriya K, Shintani Y, Fujie H, et al. Persistent viremia after recovery from self-limited acute hepatitis B. Hepatology 1998, 27(5):1377-82. 10.1002/hep.510270526, 9581694.
23. Michalak TI, Mulrooney PM, Coffin CS. Low doses of hepadnavirus induce infection of the lymphatic system that does not engage the liver. J Virol 2004, 78(4):1730-8. 10.1128/JVI.78.4.1730-1738.2004, 369489, 14747538.
24. Zerbini A, Pilli M, Boni C, Fisicaro P, Penna A, Di Vincenzo P, et al. The characteristics of the cell-mediated immune response identify different profiles of occult hepatitis B virus infection. Gastroenterology 2008, 134(5):1470-81. 10.1053/j.gastro.2008.02.017, 18355815.
25. Milich D, Liang TJ. Exploring the biological basis of hepatitis B e antigen in hepatitis B virus infection. Hepatology 2003, 38(5):1075-86. 10.1053/jhep.2003.50453, 14578844.
26. Terazawa S, Kojima M, Yamanaka T, Yotsumoto S, Okamoto H, Tsuda F, et al. Hepatitis B virus mutants with precore-region defects in two babies with fulminant hepatitis and their mothers positive for antibody to hepatitis B e antigen. Pediatr Res 1991, 29(1):5-9. 10.1203/00006450-199101000-00002, 2000259.
27. Wang JS, Chen H, Zhu QR. Transformation of hepatitis B serologic markers in babies born to hepatitis B surface antigen positive mothers. World J Gastroenterol 2005, 11(23):3582-5.
28. Zanetti AR, Mariano A, Romano L, D'Amelio R, Chironna M, Coppola RC, et al. Long-term immunogenicity of hepatitis B vaccination and policy for booster: an Italian multicentre study. Lancet 2005, 366(9494):1379-84. 10.1016/S0140-6736(05)67568-X, 16226616.
29. Kao JH, Chen DS. Hepatitis B vaccination: to boost or not to boost?. Lancet 2005, 366(9494):1337-8. 10.1016/S0140-6736(05)67544-7, 16226597.
30. Ward SM, Phalora P, Bradshaw D, Leyendeckers H, Klenerman P. Direct ex vivo evaluation of long-lived protective antiviral memory B cell responses against hepatitis B virus. J Infect Dis 2008, 198(6):813-7. 10.1086/591094, 18662131.
31. Yeo W, Chan PK, Zhong S, Ho WM, Steinberg JL, Tam JS, et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol 2000, 62(3):299-307. 10.1002/1096-9071(200011)62:3<299::AID-JMV1>3.0.CO;2-0, 11055239.
32. Hui CK, Cheung WW, Zhang HY, Au WY, Yueng YH, Leung AY, et al. Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. Gastroenterology 2006, 131(1):59-68. 10.1053/j.gastro.2006.04.015, 16831590.